FMP

FMP

Enter

INFI - Infinity Pharmaceuti...

photo-url-https://images.financialmodelingprep.com/symbol/INFI.png

Infinity Pharmaceuticals, Inc.

INFI

NASDAQ

Inactive Equity

Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Cambridge, Massachusetts.

0.008 USD

-0.0088 (-110%)

INFI Financial Statements

Quarter

2023 Q2

2023 Q1

2022 Q4

2022 Q3

Total Revenue

583k

731k

543k

712k

Cost of Revenue

352k

441k

327k

429k

Gross Profit

231k

290k

216k

283k

Operating Expenses

10.35M

11.8M

9.75M

11.16M

Research and Development

6.6M

5.85M

6.96M

7.66M

Selling, General & Administrative Expenses

3.75M

5.94M

2.79M

3.5M

Selling & Marketing Expenses

0

0

0

0

General & Administrative Expenses

3.75M

5.94M

2.79M

3.5M

Other Expenses

352k

441k

1.56M

429k

Operating Income

-10.12M

-11.51M

-9.54M

-10.88M

Total Other Income/Expenses Net

164k

462k

308k

164k

Income Before Tax

-9.96M

-11.04M

-9.23M

-10.72M

Income Tax

45k

-417k

-459k

-164k

Net Income

-9.96M

-10.63M

-8.77M

-10.55M

Basic EPS

-0.11

-0.12

-0.1

-0.12

EPS Diluted

-0.11

-0.12

-0.1

-0.12

Basic Average Shares

89.89M

89.41M

89.25M

89.39M

Diluted Average Shares

89.89M

89.41M

89.25M

89.39M

EBITDA

-10.01M

-11.4M

-9.54M

-10.77M

Retained Earning Schedule

Quarter

2023 Q2

2023 Q1

2022 Q4

2022 Q3

Retained Earnings (Previous Year)

-867M

-855.95M

-846.72M

-836M

Net Income

-9.96M

-10.63M

-8.77M

-10.55M

Stock Repurchases

0

0

0

0

Dividend Paid

0

0

0

0

Retained Earnings

-876.95M

-867M

-855.95M

-846.72M

Other Distributions

-9.96M

-11.04M

-9.23M

-10.72M

PPE Schedule

Quarter

2023 Q2

2023 Q1

2022 Q4

2022 Q3

Gross PPE

1.08M

1.29M

800k

1.7M

Annual Depreciation

106k

105k

106k

111k

Capital Expenditure

0

0

17k

0

Net PPE

976k

1.19M

677k

1.59M

Intangible and Goodwill Schedule

Quarter

2023 Q2

2023 Q1

2022 Q4

2022 Q3

Acquisitions and Adjustments

0

0

0

0

Goodwill (Previous Year)

0

0

0

0

Goodwill

0

0

0

0

All figures are in USD.

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedin
2017-2024 © Financial Modeling Prep